|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
Experimental Genetics Group
International Journal of Alzheimer's DiseaseVolume 2010 (2010);Article ID 417314, 9 pagesdoi:10.4061/2010/417314 Jaworski T, Dewachter I, Lechat B, Gees M, Kremer A, Demedts D, Borghgraef P, Devijver H, Kügler S, Patel S, Woodgett JR, Van Leuven F. 11reMYND NV, Gaston Geenslaan 1, 3001 Heverlee-Leuven, Belgium 22Ablynx NV, Technologiepark 214, 9052 Zwijnaarde-Gent, Belgium 3Probiodrug AG, Weinbergweg 22, 06120 Halle-Saale, Germany 4Amorfix Life Sciences Ltd., 3403 American Drive, Mississauga, ON, L4V1T4, Canada 55Experimental Genetics Group LEGTEGG, KULeuven, Campus Gasthuisberg ON1, 3000 Leuven, Belgium The APP[V717I] London (APP-Ld) mouse model recapitulates important pathological and clinical hallmarks of Alzheimer's disease (AD) and is therefore a valuable paradigm for evaluating therapeutic candidates. Historically, both the parenchymal and vascular amyloid deposits, and more recently, truncated and pyroglutamate-modified Abeta3(pE)-42 species, are perceived as important hallmarks of AD-pathology. Late stage symptoms are preceded by robust deficits in orientation and memory that correlate in time with Abeta oligomerization and GSK3β-mediated phosphorylation of endogenous murine Tau, all markers that have gained considerable interest during the last decade. Clinical parallels with AD patients and the value of the APP-Ld transgenic mouse model for preclinical in vivo testing of candidate drugs are discussed.  FULL TEXT |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
Copyright © Katholieke Universiteit Leuven | Comments on the content: Fred Van Leuven Production:Gabriela Casteels| Most recent update: January 23, 2012 | Disclaimer URL: http://med.kuleuven.be/legtegg/ |
